Receptos Announces Appointment of Mary Szela and Richard Heyman, Ph.D. to Board of Directors
29 July 2014 - 10:00PM
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company
developing therapeutic candidates for the treatment of immune and
metabolic diseases, today announced the appointment of Mary Szela
and Richard Heyman to the board of directors of Receptos. Ms. Szela
and Dr. Heyman will both serve as Class II directors with terms of
office expiring and to be renewed at the 2015 annual meeting of
stockholders. Ms. Szela and Dr. Heyman will also both serve as
members of the Board's Nominating and Corporate Governance
Committee.
Bill Rastetter, Ph.D., chairman of the board of directors of
Receptos, said, "We are pleased to welcome both Mary and Rich to
the Receptos board of directors. Mary's extensive marketing and
commercial expertise brings a new and valuable skillset to our
board as Receptos matures, while Rich's proven track record and
deep background in drug discovery and development will provide
valuable insight, experience and leadership. We look forward to
working with both of them."
Ms. Szela was appointed chairperson of Melinta Therapeutics in
January 2013 and transitioned to chief executive officer in April
2013. From 2010 to 2012, Ms. Szela was senior vice president of
global strategic marketing and services at the Abbott Laboratories
Pharmaceutical Products Group and also served as its senior vice
president of US Pharmaceuticals from 2008 to 2009. Prior to this
role, she served more than two decades in senior leadership roles
at Abbott Laboratories. Ms. Szela is also a member of the board of
directors of Suneva Medical. Ms. Szela earned a bachelor's degree
in nursing and a Master of Business Administration from the
University of Illinois.
Dr. Heyman currently serves as chief executive officer of
Seragon Pharmaceuticals, which he co-founded in 2013. In July 2014,
Seragon announced a definitive agreement with Roche Group whereby
Seragon will be acquired for up to $1.7 billion in transaction
value. From 2009 to 2013, Dr. Heyman was the Chief Executive
Officer and co-founder of Aragon Pharmaceuticals until its
acquisition by Johnson and Johnson for up to $1.0 billion in
transaction value. Previously, Dr. Heyman co-founded and served as
Chief Scientific Officer of X-Ceptor Therapeutics, a company that
developed compounds targeting nuclear receptors for the treatment
of metabolic diseases. X-Ceptor was acquired by Exelixis in 2004.
Before X-Ceptor, he was vice president of research at Ligand
Pharmaceuticals. Dr. Heyman was an NIH postdoctoral fellow and
staff scientist at the Salk Institute for Biological Studies and
received a Ph.D. in pharmacology from the University of Minnesota
and a bachelor of science in chemistry from the University of
Connecticut.
Receptos also announced that Amir Nashat, Sc.D., one of its
Class II directors, retired from the board of directors, effective
July 25, 2014.
Dr. Rastetter remarked, "Amir has been a great supporter of
Receptos, both as an early investor and as a board member. We very
much appreciate his leadership during a transformative period for
Receptos and thank him for his service."
About Receptos
Receptos is a biopharmaceutical company developing therapeutic
candidates for the treatment of immune and metabolic diseases. The
Company's lead program, RPC1063, is a sphingosine 1-phosphate 1
receptor (S1P1R) small molecule modulator candidate for immune
indications, including relapsing multiple sclerosis (RMS) and
inflammatory bowel disease (IBD). The Company is also developing
RPC4046, an anti-interleukin-13 (IL-13) antibody for an
allergic/immune-mediated orphan disease, eosinophilic esophagitis
(EoE). Receptos has established expertise in high resolution
protein crystal structure determination, biology and drug discovery
for G-protein-coupled receptors (GPCRs).
CONTACT: Media and Investor Contact:
Graham K. Cooper
Chief Financial Officer, Receptos
(858) 652-5708
gcooper@receptos.com
RECEPTOS, INC. (NASDAQ:RCPT)
Historical Stock Chart
From Jun 2024 to Jul 2024
RECEPTOS, INC. (NASDAQ:RCPT)
Historical Stock Chart
From Jul 2023 to Jul 2024